After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.
Having collaborated with AstraZeneca PLC on their COVID-19 vaccine, the University of Oxford will be hoping for an equally successful partnership with
GlaxoSmithKline plc after inking a deal with the other UK pharma giant to set up a new institute that will apply